Antidepressant and antipsychotic drug prescribing and diabetes outcomes: A systematic review of observational studies
Authors' conclusion
Studies of antidepressant and antipsychotic drug prescribing in relation to diabetes outcomes are scarce, with shortcomings and mixed findings. Until further evidence is available, people with diabetes prescribed antidepressants and antipsychotics should receive monitoring and appropriate treatment of risk factors and screening for complications as recommended in general diabetes guidelines.
Study context
- Population
- People with T2D; PubMed, EMBASE and PsycINFO searched to 15th August 2022
- Participants
- 18 studies
- Comparison
- Antidepressant or antipsychotic drug prescribing and T2D outcomes
- Antidepressantsn = 14
- Antipsychoticsn = four
- Outcome
- Diabetes outcomes
Methodological detailsnarrative synthesis, Newcastle-Ottawa scale quality assessment
- Narrative synthesis
- Newcastle-Ottawa scale quality assessment
Pooled result
As reported in the abstract
- Antidepressant prescribing may be associated with increased risk of macrovascular disease
- Evidence on antidepressant and antipsychotic prescribing and glycaemic control was mixed
- Few studies reported microvascular outcomes and risk factors other than glycaemic control
- 11 cohort, 1 self-controlled before and after, 2 case-control, 4 cross-sectional studies; variable quality, highly heterogeneous
Original publication
Antidepressant and antipsychotic drug prescribing and diabetes outcomes: A systematic review of observational studies. Diabetes Res Clin Pract. Published 31 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →